Full Press Release Details
ROCKVILLE, Md., Nov. 12, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Md., November 12, 2014
- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer, as well as autoimmune disorders and infectious diseases,
today announced that Scott Koenig, M.D., Ph.D., President and CEO
will present at the Stifel 2014 Healthcare Conference in New York,
NY. The presentation will take place on Tuesday, November 18, 2014
at 10:55 a.m. Eastern Time.
A live webcast of MacroGenics' presentation may
be accessed under "Events & Presentations" in the Investor
Relations section of the Company's website at
http://ir.macrogenics.com/events.cfm. MacroGenics will maintain
an archived replay of the webcast on its website for 30 days after
About MacroGenics, Inc.
MacroGenics is a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer, as well as autoimmune disorders and infectious diseases.
The Company generates its pipeline of product candidates from its
proprietary suite of next-generation antibody-based technology
platforms. The combination of MacroGenics' technology
platforms and protein engineering expertise has allowed the Company
to generate promising product candidates and enter into several
strategic collaborations with global pharmaceutical and
biotechnology companies. For more information, please see the
Company's website at www.macrogenics.com. MacroGenics is a
registered trademark of MacroGenics, Inc.
Cautionary Note on Forward-Looking
Any statements in this press release about
future expectations, plans and prospects for the Company, including
statements about the Company's strategy, future operations,
clinical development of the Company's therapeutic candidates,
milestone or opt-in payments from the Company's collaborators, the
Company's future expectations and plans and prospects and other
statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and enrollment of future
clinical trials, expectations of expanding ongoing clinical trials,
availability and timing of data from ongoing clinical trials,
expectations for regulatory approvals, other matters that could
affect the availability or commercial potential of the Company's
product candidates and other risk factors described in the
Company's filings with the Securities and Exchange Commission,
including those discussed in the "Risk Factors" section of the
Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission on March 20, 2014 and the subsequent Quarterly
Reports on Form 10-Q. In addition, the forward-looking statements
included in this press release represent the Company's views as of
the date hereof. The Company anticipates that subsequent events and
developments will cause the Company's views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company's views as of
any date subsequent to the date hereof.